These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34614441)

  • 1. Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept.
    Cojutti PG; Rinaldi M; Gatti M; Tedeschi S; Viale P; Pea F
    Int J Antimicrob Agents; 2021 Nov; 58(5):106445. PubMed ID: 34614441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration.
    Peeters O; Ferry T; Ader F; Boibieux A; Braun E; Bouaziz A; Karsenty J; Forestier E; Laurent F; Lustig S; Chidiac C; Valour F;
    BMC Infect Dis; 2016 Nov; 16(1):622. PubMed ID: 27809799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
    Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Problems with teicoplanin in the treatment of osteoarticular infections caused by methicillin-resistant S. aureus].
    Gómez J; Climent C; Herrero F; Ruano L
    Enferm Infecc Microbiol Clin; 1992 Nov; 10(9):567-8. PubMed ID: 1489810
    [No Abstract]   [Full Text] [Related]  

  • 5. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prolonged treatment with dalbavancin in prosthetic hip infection by methicillin-resistant Staphylococcus epidermidis].
    Trujillano Ruiz A; Mesquida Riera J; Serrano Fabiá MA; Riera Pérez E; Mejía Benard A; Taberner Ferrer MD
    Rev Esp Quimioter; 2019 Apr; 32(2):203-204. PubMed ID: 30868837
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment with dalbavancin in a patient with septic thrombophlebitis of the internal jugular vein due to Staphylococcus aureus after insertion of an implantable cardioverter defibrillator.
    Martínez-Sanz J; Gijón de la Santa L; Torralba M
    Enferm Infecc Microbiol Clin (Engl Ed); 2018; 36(6):389-390. PubMed ID: 29132942
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.
    Almangour TA; Fletcher V; Alessa M; Alhifany AA; Tabb D
    Am J Case Rep; 2017 Dec; 18():1315-1319. PubMed ID: 29222405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dalbavancin treatment of prosthetic knee infection due to oxacillin-resistant Staphylococcus epidermidis.
    Ramírez Hidalgo M; Jover-Sáenz A; García-González M; Barcenilla-Gaite F
    Enferm Infecc Microbiol Clin (Engl Ed); 2018 Feb; 36(2):142-143. PubMed ID: 28600171
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of MRSA infections].
    Borde JP; Kern WV
    Dtsch Med Wochenschr; 2012 Dec; 137(49):2553-7. PubMed ID: 23143638
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections.
    Fernández J; Greenwood-Quaintance KE; Patel R
    Diagn Microbiol Infect Dis; 2016 Aug; 85(4):449-51. PubMed ID: 27241369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The comparative costs of vancomycin treatment versus teicoplanin in osteoarticular infection caused by methicillin-resistant staphylococci].
    Pham Dang C; Gouin F; Touchais S; Richard C; Potel G
    Pathol Biol (Paris); 2001 Sep; 49(7):587-96. PubMed ID: 11642024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dalbavancin combined with linezolid in prosthetic-hip infection.
    Carrión Madroñal IM; Sánchez Del Moral R; Abad Zamora JM; Martínez Marcos FJ
    Rev Esp Quimioter; 2020 Apr; 33(2):147-148. PubMed ID: 32157859
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic potential of dalbavancin in a rat model of methicillin-resistant Staphylococcus aureus (MRSA)-osteomyelitis.
    Silva V; Miranda C; Antão HS; Guimarães J; Prada J; Pires I; Maltez L; Pereira JE; Capelo JL; Igrejas G; Poeta P
    Int J Antimicrob Agents; 2020 Jul; 56(1):106021. PubMed ID: 32439480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for subacute and chronic staphylococcal infections.
    Cojutti PG; Gatti M; Punt N; Douša J; Zamparini E; Tedeschi S; Viale P; Pea F
    Int J Antimicrob Agents; 2024 Jan; 63(1):107038. PubMed ID: 37981075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-times weekly teicoplanin as outpatient treatment of chronic osteoarticular infections.
    Tascini C; Tagliaferri E; Di Paolo A; Ciofi L; Del Tacca M; Lambelet P; Menichetti F
    J Chemother; 2009 Aug; 21(4):421-5. PubMed ID: 19622461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains.
    Citron DM; Tyrrell KL; Goldstein EJ
    Diagn Microbiol Infect Dis; 2014 Aug; 79(4):438-40. PubMed ID: 24972854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections.
    Gatti M; Viale P; Cojutti PG; Zamparini E; De Paolis M; Giannella M; Pea F; Tedeschi S
    Int J Antimicrob Agents; 2023 May; 61(5):106773. PubMed ID: 36878410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dalbavancin was effective and safe after one year of treatment in a complicated osteoarticular infection caused by methicillin-resistant Staphylococcus aureus.
    Matesanz M; Poza A; Iñurrieta A; Fernández-Diaz E; Arroyo M; Domínguez I; Candel FJ
    Rev Esp Quimioter; 2021 Aug; 34(4):396-399. PubMed ID: 33956412
    [No Abstract]   [Full Text] [Related]  

  • 20. [Child osteoarticular infections: statements and perspectives].
    Cohen R; Grimprel E
    Arch Pediatr; 2007 Oct; 14 Suppl 2():S79-80. PubMed ID: 17956822
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.